LD-013

N/A

Report date: 2025/05/29 11:47:52

Base Information

Drug NameLD-013

Drug Alias NameMesothelin specific chimeric antigen receptor T-cell therapyLD013LD-013

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-Mesothelin

TargetsMesothelin

Therapy Area/IndicationsSolid tumoursOvarian Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesNanjing Blue Shield Biotech Co Ltd

China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Blue Shield Biotech Co Ltd

Inactive CompaniesN/A

Active IndicationsOvarian Neoplasms

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A